Medtronic plc (MDT)
What's Next For Medtronic Stock After An Upbeat Q1?
Medtronic (NYSE: MDT) recently reported its Q1 fiscal 2025 results (fiscal ends in April), with revenues and earnings exceeding our estimates. The company reported revenue of $7.9 billion and adjusted earnings of $1.23 per share, compared to our estimates of $7.9 billion and $1.21, respectively.
Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look at Key Metrics (Revised)
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed
Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.
Demand for Medtronic's Medical Devices Lifts Profit and Sales
Medtronic (MDT) shares advanced in intraday trading Tuesday as the medical technology firm posted better-than-expected results and raised its guidance on strong demand for its medical devices.
Medtronic plc (MDT) Q1 2025 Earnings Call Transcript
Medtronic plc (NYSE:MDT ) Q1 2025 Earnings Conference Call August 20, 2024 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Gary Corona - Interim Chief Financial Officer Brad Welnick - VP, IR Que Dallara - EVP and President, Diabetes Operating Unit Sean Salmon - EVP and President, Cardiovascular Portfolio Mike Marinaro - EVP and President, Medical Surgical Portfolio and Surgical Operating Unit Conference Call Participants Vijay Kumar - Evercore ISI Robert Marcus - JPMorgan Travis Steed - Bank of America Securities Danielle Antalffy - UBS Securities Lawrence Biegelsen - Wells Fargo David Rescott - Baird Equity Research Matt Taylor - Jefferies David Roman - Goldman Sachs Jayson Bedford - Raymond James Joanne Wuensch - Citi Matt Miksic - Barclays Patrick Wood - Morgan Stanley Ryan Weispfenning Good morning and welcome to another Medtronic Earnings Day. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations, and I appreciate that you're joining us this morning for our Fiscal 2025 First Quarter Video Earnings Webcast.
Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Surpasses Q1 Earnings and Revenue Estimates
Medtronic (MDT) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.20 per share a year ago.
Medtronic lifts profit forecast on medical devices demand, new launches
Medtronic slightly lifted the lower end of its annual profit forecast on Tuesday, banking on sustained demand for its medical devices and growth from its new launches.
Medtronic's stock gains after profit and sales topped forecasts, and the full-year outlook was nudged up
Shares of Medtronic PLC MDT, +0.26% gained 0.8% in premarket trading Tuesday, after the cardiovascular and medical surgical products company topped fiscal first-quarter profit and sales expectations and nudged up its full-year outlook. Net income for the quarter to July 26 rose to $1.04 billion, or 80 cents a share, from $791 million, or 59 cents a share, in the year-ago period.
Should You Buy, Sell or Hold Medtronic (MDT) Before Q1 Earnings?
Medtronic's (MDT) first-quarter profits might have been dented by higher costs and expenses originating from macro issues and geopolitical complexities. However, innovations may have boosted the top line.
Medtronic: Healthy Vital Signs Heading Into Earnings
Medtronic stock underperformed the market, up only 4% in the past year. The options market predicts a 3.3% stock price swing post-earnings. Mid-single-digit EPS growth, rising dividends, and historically high yield for Medtronic are positive factors.
Medtronic: Still A Buy Before Earnings
Medtronic is a strong option for investors seeking both low volatility and consistent dividend growth. I am quite positive about recent developments related to new crucial FDA approvals. Various valuation approaches suggest that the current share price is attractive.
